Post written by: BioTech Health X
You May Also Like
Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery & T Cell Receptors
- 3 minute read
The collaboration between Repertoire and Yale seeks to identify novel antigenic reactivity of T cells in patients with…
Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
- 3 minute read
Table of Contents Hide About BrickellWhat This Means for Brickell Biotech ShareholdersUnderstanding Nasdaq Minimum Bid Price RequirementWhy Nasdaq…
Aerobiotix Announces Raise of $25M Growth Equity Financing Led by Healthcare Investment Firm Vivo Capital
- 3 minute read
Aerobiotix, a pioneer in airborne infection control products that provide real-time, in room solutions for hospitals, ASCs, long…
Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
- 5 minute read
Table of Contents Hide FORTRESS Fibromyalgia Clinical Trial OverviewVirios Therapeutics Trial FailureIMC-1 Safety & EfficacyVirios Therapeutics Executive Commentary…
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
- 3 minute read
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
PharmaCyte Biotech Announces Uplist to Nasdaq Capital Market and Public Offering
- 3 minute read
Biotechnology company PharmaCyte Biotech, Inc. (OTCQB: PMCBD), a company concentrated on creating cellular therapies for cancer cells and…